Asia-Pacific Clinical Biomarkers Market - Analysis and Forecast, 2023-2033
Hard copy option is available on any of the options above at an additional charge of $500. Please email us at [email protected] with your request.
This report will be delivered in 1-5 working days.
Introduction to Asia-Pacific Clinical Biomarkers Market
The Asia-Pacific clinical biomarkers market was valued at $3.28 billion in 2023 and is expected to reach $7.95 billion by 2033, growing at a CAGR of 9.27% between 2023 and 2033. Clinical biomarkers are quantifiable biological parameters that aid in understanding the progression and early diagnosis of diseases. These biomarkers, particularly molecular ones, offer new targets for characterizing diseases and for drug discovery and development.
Market Introduction
The Asia-Pacific (APAC) clinical biomarkers market is rapidly expanding, driven by advancements in biotechnology, increased healthcare spending, and a growing focus on personalized medicine. Countries like China, Japan, and India are at the forefront, with substantial investments in research and development and robust clinical trial activities. The rising prevalence of chronic diseases, such as cancer and cardiovascular conditions, fuels the demand for early diagnostic tools and targeted therapies. Government initiatives and collaborations between academic institutions and biopharmaceutical companies further propel market growth. The integration of advanced technologies, such as next-generation sequencing and bioinformatics, enhances the identification and validation of novel biomarkers, making the APAC region a crucial player in the clinical biomarkers landscape.
Market Segmentation:
Segmentation 1: by Country
Growth/Marketing Strategy: Product launches and upgradations accounted for the maximum number of key developments. Numerous synergistic activities, fundings, and acquisitions of the market have also been tracked during the same time period.
Competitive Strategy: The clinical biomarkers market is a highly fragmented market, with many smaller and private companies constantly entering the market. Key players in the Asia-Pacific clinical biomarkers market analyzed and profiled in the study involve established players that offer various kinds of products and services.
Key Market Players and Competition Synopsis
The companies that are profiled have been selected based on inputs gathered from primary experts and analyzing company coverage, product portfolio, and market penetration.
Some prominent names established in this market are
This report will be delivered in 1-5 working days.
Introduction to Asia-Pacific Clinical Biomarkers Market
The Asia-Pacific clinical biomarkers market was valued at $3.28 billion in 2023 and is expected to reach $7.95 billion by 2033, growing at a CAGR of 9.27% between 2023 and 2033. Clinical biomarkers are quantifiable biological parameters that aid in understanding the progression and early diagnosis of diseases. These biomarkers, particularly molecular ones, offer new targets for characterizing diseases and for drug discovery and development.
Market Introduction
The Asia-Pacific (APAC) clinical biomarkers market is rapidly expanding, driven by advancements in biotechnology, increased healthcare spending, and a growing focus on personalized medicine. Countries like China, Japan, and India are at the forefront, with substantial investments in research and development and robust clinical trial activities. The rising prevalence of chronic diseases, such as cancer and cardiovascular conditions, fuels the demand for early diagnostic tools and targeted therapies. Government initiatives and collaborations between academic institutions and biopharmaceutical companies further propel market growth. The integration of advanced technologies, such as next-generation sequencing and bioinformatics, enhances the identification and validation of novel biomarkers, making the APAC region a crucial player in the clinical biomarkers landscape.
Market Segmentation:
Segmentation 1: by Country
- China
- India
- Japan
- South Korea
- Australia
- Rest-of-Asia-Pacific
Growth/Marketing Strategy: Product launches and upgradations accounted for the maximum number of key developments. Numerous synergistic activities, fundings, and acquisitions of the market have also been tracked during the same time period.
Competitive Strategy: The clinical biomarkers market is a highly fragmented market, with many smaller and private companies constantly entering the market. Key players in the Asia-Pacific clinical biomarkers market analyzed and profiled in the study involve established players that offer various kinds of products and services.
Key Market Players and Competition Synopsis
The companies that are profiled have been selected based on inputs gathered from primary experts and analyzing company coverage, product portfolio, and market penetration.
Some prominent names established in this market are
- BGI
- Novogene Co., Ltd.
Executive Summary
1 MARKET
2 MARKET SCOPE
2.1 Key Questions Answered in the Report
3 RESEARCH METHODOLOGY
3.1 Data Sources
3.1.1 Primary Data Source
3.1.2 Secondary Data Sources
3.1.2.1 Open Sources
3.2 Market Estimation Model
3.3 Criteria for Company Profiling
4 MARKET OVERVIEW
4.1 Introduction
4.2 Clinical Biomarkers Approaches in Precision Medicine
4.3 Market Size Potential for Clinical Biomarkers, 2022-2033
4.4 COVID-19 Impact on Clinical Biomarkers Market
4.4.1 COVID-19 Impact on Market Size
4.5 Market Trends
4.5.1 Integration of Artificial Intelligence in Biomarker Discovery
4.5.2 Increasing Biomarkers Usage in Precision Medicine
4.5.3 Technologies Being Used in Clinical Biomarker Testing
4.5.4 Clinical Biomarker Discovery Making Early Disease Diagnosis Possible
5 REGION
5.1 Overview
5.2 Asia-Pacific
5.2.1 China
5.2.2 India
5.2.3 Japan
5.2.4 South Korea
5.2.5 Australia
5.2.6 Rest-of-Asia-Pacific
6 MARKET - COMPANY PROFILES
6.1 Overview
6.2 BGI
6.2.1 Company Overview
6.2.2 Role of BGI in the Clinical Biomarkers Market
6.2.3 Corporate Strategies
6.2.3.1 Product Launch
6.2.4 Analyst’s Perspective
6.3 Novogene Co., Ltd.
6.3.1 Company Overview
6.3.2 Role of Novogene Co., Ltd. in the Clinical Biomarkers Market
6.3.3 Analyst’s Perspective
List of Figures
Figure 1: Clinical Biomarkers Market (by Region), $Billion, 2022 and 2033
Figure 2: Asia-Pacific Clinical Biomarkers Market Research Methodology
Figure 3: Primary Research Methodology
Figure 4: Bottom-Up Approach (Segment-Wise Analysis)
Figure 5: Top-Down Approach (Segment-Wise Analysis)
Figure 6: Biomarkers Used in Various Clinical Areas
Figure 7: Asia-Pacific Clinical Biomarkers Market, $Billion, 2022-2033
Figure 8: Impact of COVID-19 on Clinical Biomarkers Market
Figure 9: Usage of Artificial Intelligence (AI) in Biomarker Discovery
Figure 10: Use of Clinical Biomarkers in Personalized Medicine
Figure 11: Prevalence vs. Age-Standardized Death Rate of Cancer Globally, % Share, 2010-2019
Figure 12: Clinical Biomarkers Market Snapshot (by Region), $Billion, 2022-2033
Figure 13: Clinical Biomarkers Market (by Region), $Billion, 2022-2033
Figure 14: Clinical Biomarkers Market (by Region), $Billion, 2022 and 2033
Figure 15: Asia-Pacific Clinical Biomarkers Market, $Billion, 2022-2033
Figure 16: Asia-Pacific Clinical Biomarkers Market (by Country), $Billion, 2022-2033
Figure 17: Asia-Pacific: Market Dynamics
Figure 18: China Clinical Biomarkers Market, $Billion, 2022-2033
Figure 19: India Clinical Biomarkers Market, $Billion, 2022-2033
Figure 20: Japan Clinical Biomarkers Market, $Billion, 2022-2033
Figure 21: South Korea Clinical Biomarkers Market, $Billion, 2022-2033
Figure 22: Australia Clinical Biomarkers Market, $Billion, 2022-2033
Figure 23: Rest-of-Asia-Pacific Clinical Biomarkers Market, $Billion, 2022-2033
Figure 24: Total Number of Companies Profiled
Figure 25: BGI: Service Portfolio
Figure 26: Novogene Co., Ltd.: Service Portfolio
List of Tables
Table 1: COVID-19 Impact on Clinical Biomarkers Market, 2020-2033
Table 2: List of Product/Service Offered and its Technology
1 MARKET
2 MARKET SCOPE
2.1 Key Questions Answered in the Report
3 RESEARCH METHODOLOGY
3.1 Data Sources
3.1.1 Primary Data Source
3.1.2 Secondary Data Sources
3.1.2.1 Open Sources
3.2 Market Estimation Model
3.3 Criteria for Company Profiling
4 MARKET OVERVIEW
4.1 Introduction
4.2 Clinical Biomarkers Approaches in Precision Medicine
4.3 Market Size Potential for Clinical Biomarkers, 2022-2033
4.4 COVID-19 Impact on Clinical Biomarkers Market
4.4.1 COVID-19 Impact on Market Size
4.5 Market Trends
4.5.1 Integration of Artificial Intelligence in Biomarker Discovery
4.5.2 Increasing Biomarkers Usage in Precision Medicine
4.5.3 Technologies Being Used in Clinical Biomarker Testing
4.5.4 Clinical Biomarker Discovery Making Early Disease Diagnosis Possible
5 REGION
5.1 Overview
5.2 Asia-Pacific
5.2.1 China
5.2.2 India
5.2.3 Japan
5.2.4 South Korea
5.2.5 Australia
5.2.6 Rest-of-Asia-Pacific
6 MARKET - COMPANY PROFILES
6.1 Overview
6.2 BGI
6.2.1 Company Overview
6.2.2 Role of BGI in the Clinical Biomarkers Market
6.2.3 Corporate Strategies
6.2.3.1 Product Launch
6.2.4 Analyst’s Perspective
6.3 Novogene Co., Ltd.
6.3.1 Company Overview
6.3.2 Role of Novogene Co., Ltd. in the Clinical Biomarkers Market
6.3.3 Analyst’s Perspective
List of Figures
Figure 1: Clinical Biomarkers Market (by Region), $Billion, 2022 and 2033
Figure 2: Asia-Pacific Clinical Biomarkers Market Research Methodology
Figure 3: Primary Research Methodology
Figure 4: Bottom-Up Approach (Segment-Wise Analysis)
Figure 5: Top-Down Approach (Segment-Wise Analysis)
Figure 6: Biomarkers Used in Various Clinical Areas
Figure 7: Asia-Pacific Clinical Biomarkers Market, $Billion, 2022-2033
Figure 8: Impact of COVID-19 on Clinical Biomarkers Market
Figure 9: Usage of Artificial Intelligence (AI) in Biomarker Discovery
Figure 10: Use of Clinical Biomarkers in Personalized Medicine
Figure 11: Prevalence vs. Age-Standardized Death Rate of Cancer Globally, % Share, 2010-2019
Figure 12: Clinical Biomarkers Market Snapshot (by Region), $Billion, 2022-2033
Figure 13: Clinical Biomarkers Market (by Region), $Billion, 2022-2033
Figure 14: Clinical Biomarkers Market (by Region), $Billion, 2022 and 2033
Figure 15: Asia-Pacific Clinical Biomarkers Market, $Billion, 2022-2033
Figure 16: Asia-Pacific Clinical Biomarkers Market (by Country), $Billion, 2022-2033
Figure 17: Asia-Pacific: Market Dynamics
Figure 18: China Clinical Biomarkers Market, $Billion, 2022-2033
Figure 19: India Clinical Biomarkers Market, $Billion, 2022-2033
Figure 20: Japan Clinical Biomarkers Market, $Billion, 2022-2033
Figure 21: South Korea Clinical Biomarkers Market, $Billion, 2022-2033
Figure 22: Australia Clinical Biomarkers Market, $Billion, 2022-2033
Figure 23: Rest-of-Asia-Pacific Clinical Biomarkers Market, $Billion, 2022-2033
Figure 24: Total Number of Companies Profiled
Figure 25: BGI: Service Portfolio
Figure 26: Novogene Co., Ltd.: Service Portfolio
List of Tables
Table 1: COVID-19 Impact on Clinical Biomarkers Market, 2020-2033
Table 2: List of Product/Service Offered and its Technology
